Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00427934




Registration number
NCT00427934
Ethics application status
Date submitted
25/01/2007
Date registered
29/01/2007
Date last updated
5/11/2014

Titles & IDs
Public title
Maraviroc in Rheumatoid Arthritis
Scientific title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
Secondary ID [1] 0 0
A4001056
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Arthritis, Rheumatoid 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0
Osteoarthritis
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Maraviroc
Treatment: Drugs - Maraviroc Placebo

Placebo comparator: 2 -

Experimental: 1 - This study was divided into two components: safety/pharmacokinetic (PK) and proof-of-concept (POC). In the safety/PK component either 150 mg or 300 mg tablets of maraviroc was administered twice a day (BID) to 16 rheumatoid arthritis subjects for 4 weeks.


Treatment: Drugs: Maraviroc
300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.

Treatment: Drugs: Maraviroc Placebo
Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
American College of Rheumatology (ACR) 20% Responders at Week 12
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
ACR 20% Responders at Weeks 1, 2, 4, and 8
Timepoint [1] 0 0
Weeks 1, 2, 4, and 8
Secondary outcome [2] 0 0
ACR 50% Responders at Weeks 1, 2, 4, 8, and 12
Timepoint [2] 0 0
Weeks 1, 2, 4, 8, and 12
Secondary outcome [3] 0 0
ACR 70% Responders at Weeks 1, 2, 4, 8, and 12
Timepoint [3] 0 0
Weeks 1, 2, 4, 8, and 12
Secondary outcome [4] 0 0
Change From Baseline in Tender/Painful Joint Count at Weeks 1, 2, 4, 8, and 12
Timepoint [4] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [5] 0 0
Change From Baseline in Swollen Joint Count at Weeks 1, 2, 4, 8, and 12
Timepoint [5] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [6] 0 0
Change From Baseline in Patient's Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
Timepoint [6] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [7] 0 0
Change From Baseline in Patient's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
Timepoint [7] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [8] 0 0
Change From Baseline in Physician's Global Assessment of Arthritis Pain at Weeks 1, 2, 4, 8, and 12
Timepoint [8] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [9] 0 0
Change From Baseline in HAQ-DI at Weeks 1, 2, 4, 8, and 12
Timepoint [9] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [10] 0 0
Change From Baseline in CRP at Weeks 1, 2, 4, 8, and 12
Timepoint [10] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [11] 0 0
Change From Baseline in Disease Activity Score Using CRP (DAS28-4[CRP]) at Weeks 1, 2, 4, 8, and 12
Timepoint [11] 0 0
Baseline, Weeks 1, 2, 4, 8, and 12
Secondary outcome [12] 0 0
Change From Baseline in Mean Orthostatic Blood Pressure (BP)
Timepoint [12] 0 0
Baseline, 16 weeks
Secondary outcome [13] 0 0
Change From Baseline in Mean Heart Rate
Timepoint [13] 0 0
Baseline, 16 weeks
Secondary outcome [14] 0 0
Number of Subjects With Categorical Absolute Vital Signs and Vital Sign Changes Compared to Baseline
Timepoint [14] 0 0
Baseline, 16 weeks
Secondary outcome [15] 0 0
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (RR Interval, PR Interval, QRS Complex, QT Interval, Corrected QT [QTc] Interval, QTcB Interval [Bazett's Correction], QTcF Interval [Fridericia's Correction]).
Timepoint [15] 0 0
Baseline, 16 weeks
Secondary outcome [16] 0 0
Change From Baseline in 12-Lead Electrocardiogram (ECG) Parameters (Heart Rate).
Timepoint [16] 0 0
Baseline, 16 weeks
Secondary outcome [17] 0 0
Number of Subjects With Categorical Absolute ECG Parameters and ECG Changes Compared to Baseline
Timepoint [17] 0 0
Baseline, 16 weeks
Secondary outcome [18] 0 0
Change From Baseline in Short Form-36 (SF-36) Physical Component Summary at Weeks 4 and 12
Timepoint [18] 0 0
Baseline, Weeks 4 and 12
Secondary outcome [19] 0 0
Change From Baseline in SF-36 Mental Component Summary at Weeks 4 and 12
Timepoint [19] 0 0
Baseline, Weeks 4 and 12
Secondary outcome [20] 0 0
Number of Subjects With Withdrawal From Study Due to Lack of Efficacy
Timepoint [20] 0 0
16 weeks
Secondary outcome [21] 0 0
Survival Analysis of Time to Withdrawal: Proportion of Subjects Who Did Not Withdraw From the Study Due to Lack of Efficacy.
Timepoint [21] 0 0
Weeks 1 to 12
Secondary outcome [22] 0 0
Area Under the Plasma Concentration-Time Profile From Time Zero to Four Hours Postdose (AUC 0-4) for MTX at Screening and Week 1 and Maraviroc at Week 1
Timepoint [22] 0 0
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Secondary outcome [23] 0 0
Maximum Observed Concentration (Cmax) During the Dosing Interval for MTX at Screening and Week 1 and Maraviroc at Week 1
Timepoint [23] 0 0
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)
Secondary outcome [24] 0 0
Time for Cmax (Tmax) for MTX at Screening and Week 1 and Maraviroc at Week 1
Timepoint [24] 0 0
Screening (1, 2, 3, and 4 hours post-dose), Week 1 (0.5, 1, 2, 3, and 4 hours post-dose)

Eligibility
Key inclusion criteria
* Must be legal age of consent
* Must have active rheumatoid arthritis based upon the American College of Rheumatology (ACR) 1987 (Revised Criteria); minimum disease criteria required for entry into the efficacy component of the study
* Must meet ACR 1991 Revised Criteria for Global Functional Status in RA, Class I, II, or III
* Must be receiving methotrexate for at least 12 weeks duration and on a stable dose for 4 weeks.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Diagnosed with any other inflammatory arthritis or a secondary non-inflammatory arthritis that would interfere with disease activity assessments.
* Subject receiving prior treatment with certain medications for rheumatoid arthritis
* Tuberculosis and/or a positive tuberculin reaction
* Significant trauma or major surgery within 2 months
* History of alcohol and/or drug abuse outside of a defined period of abstinence
* History of or a finding at screening of postural hypotension
* Any condition that would affect the oral absorption of the drug
* History of cancer and in remission less than 3 years or Grade III-IV congestive heart failure
* Having an infection of human immunodeficiency virus (HIV), Hepatitis B or C or evidence of any active infection
* Abnormalities of clinical or laboratory assessments completed at the screening visit such as elevated liver enzymes, decreased hemoglobin or an abnormal ECG
* Having a positive chemokine receptor 5 (CCR5) delta 32 mutation
* Requiring the use of certain medications
* Lactating or pregnant women or subjects have reproductive potential unwilling to use an adequate method of birth control
* Chronic or recent serious or life-threatening infection; severe , progressive and/or uncontrollable renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological disease within 12 weeks of the first dose.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/10/2008
Sample size
Target
Accrual to date
Final
128
Recruitment in Australia
Recruitment state(s)
QLD,SA,TAS
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Maroochydore
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Woodville
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Hobart
Recruitment postcode(s) [1] 0 0
4558 - Maroochydore
Recruitment postcode(s) [2] 0 0
5011 - Woodville
Recruitment postcode(s) [3] 0 0
7001 - Hobart
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Nebraska
Country [9] 0 0
United States of America
State/province [9] 0 0
Nevada
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
North Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
North Dakota
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
Germany
State/province [14] 0 0
Berlin
Country [15] 0 0
Germany
State/province [15] 0 0
Leipzig
Country [16] 0 0
India
State/province [16] 0 0
Andhra Pradesh
Country [17] 0 0
India
State/province [17] 0 0
Karnataka
Country [18] 0 0
Italy
State/province [18] 0 0
Genova
Country [19] 0 0
Italy
State/province [19] 0 0
Pavia
Country [20] 0 0
Mexico
State/province [20] 0 0
Jalisco
Country [21] 0 0
Portugal
State/province [21] 0 0
Coimbra
Country [22] 0 0
Portugal
State/province [22] 0 0
Lisboa
Country [23] 0 0
Portugal
State/province [23] 0 0
Lisbon
Country [24] 0 0
Spain
State/province [24] 0 0
A Coruña
Country [25] 0 0
Spain
State/province [25] 0 0
Barcelona
Country [26] 0 0
Spain
State/province [26] 0 0
Madrid
Country [27] 0 0
Spain
State/province [27] 0 0
Sevilla
Country [28] 0 0
Ukraine
State/province [28] 0 0
Dnipropetrovsk
Country [29] 0 0
Ukraine
State/province [29] 0 0
Kharkiv
Country [30] 0 0
Ukraine
State/province [30] 0 0
Simferopol

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.
Trial website
https://clinicaltrials.gov/study/NCT00427934
Trial related presentations / publications
Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685.
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00427934